Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial - 31/12/13

Doi : 10.1016/S1470-2045(13)70551-5

Jason R Westin, MD ^a,^{^{*
Contributed equally}}, Fuliang Chu, PhD ^a,^b,^{^{*
Contributed equally}}, Min Zhang, PhD ^a,^b, Luis E Fayad, MD ^a, Larry W Kwak, ProfMD ^a,^b, Nathan Fowler, MD ^a, Jorge Romaguera, ProfMD ^a, Fredrick Hagemeister, ProfMD ^a, Michelle Fanale, MD ^a, Felipe Samaniego, MD ^a, Lei Feng, MS ^c, Veerabhadran Baladandayuthapani, PhD ^c, Zhiqiang Wang, PhD ^a,^b, Wencai Ma, PhD ^a,^b, Yanli Gao, MS ^a, Michael Wallace, ProfMD ^d, Luis M Vence, PhD ^b,^e, Laszlo Radvanyi, ProfPhD ^b,^e, Tariq Muzzafar, MD ^f, Rinat Rotem-Yehudar, PhD ^g, R Eric Davis, MD ^a,^b,^{^{†
Contributed equally}}, Sattva S Neelapu, DrMD ^a,^b,^⁎,^{^{†
Contributed equally}}

^a Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^b Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^c Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^d Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^e Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^f Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

^g Cure Tech, Yavne, Israel

^* Correspondence to: Dr Sattva S Neelapu, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Summary

Background

Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints might include effects of programmed cell death 1 (PD1), a co-inhibitory receptor that impairs T-cell function and is highly expressed on intratumoral T cells. We did this phase 2 trial to investigate the activity of pidilizumab, a humanised anti-PD1 monoclonal antibody, with rituximab in patients with relapsed follicular lymphoma.

Methods

We did this open-label, non-randomised trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Adult (≥18 years) patients with rituximab-sensitive follicular lymphoma relapsing after one to four previous therapies were eligible. Pidilizumab was administered at 3 mg/kg intravenously every 4 weeks for four infusions, plus eight optional infusions every 4 weeks for patients with stable disease or better. Starting 17 days after the first infusion of pidilizumab, rituximab was given at 375 mg/m² intravenously weekly for 4 weeks. The primary endpoint was the proportion of patients who achieved an objective response (complete response plus partial response according to Revised Response Criteria for Malignant Lymphoma). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00904722.

Findings

We enrolled 32 patients between Jan 13, 2010, and Jan 20, 2012. Median follow-up was 15·4 months (IQR 10·1–21·0). The combination of pidilizumab and rituximab was well tolerated, with no autoimmune or treatment-related adverse events of grade 3 or 4. The most common adverse events of grade 1 were anaemia (14 patients) and fatigue (13 patients), and the most common adverse event of grade 2 was respiratory infection (five patients). Of the 29 patients evaluable for activity, 19 (66%) achieved an objective response: complete responses were noted in 15 (52%) patients and partial responses in four (14%).

Interpretation

The combination of pidilizumab plus rituximab is well tolerated and active in patients with relapsed follicular lymphoma. Our results suggest that immune checkpoint blockade is worthy of further study in follicular lymphoma.

Funding

National Institutes of Health, Leukemia and Lymphoma Society, Cure Tech, and University of Texas MD Anderson Cancer Center.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Study design and participants

Procedures

Statistical analysis

Role of the funding source

Results

Discussion

Export

Vol 15 - N° 1

P. 69-77 - janvier 2014 Retour au numéro

Article précédent

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts, Mark A Socinski, Paul L Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor-Eliade Ciuleanu, Lionel Bosquée, José Manuel Trigo, Alexander Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Ernst Erich Eberhardt, Christoph Helwig, Andreas Schröder, Frances A Shepherd, on behalf of the START trial team †

| Article suivant

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E R Ford, Andrea Marshall, John A Bridgewater, Tobias Janowitz, Fareeda Y Coxon, Jonathan Wadsley, Wasat Mansoor, David Fyfe, Srinivasan Madhusudan, Gary W Middleton, Daniel Swinson, Stephen Falk, Ian Chau, David Cunningham, Paula Kareclas, Natalie Cook, Jane M Blazeby, Janet A Dunn, on behalf of the COUGAR-02 Investigators

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial - 31/12/13

Summary

Background

Methods

Findings

Interpretation

Funding

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL